{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T07:05:31Z","timestamp":1786863931864,"version":"build-2736575974"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-03849-6","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T16:07:22Z","timestamp":1738426042000},"page":"2904-2912","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Association of tumor treating fields (TTFields) therapy with overall survival in newly diagnosed glioblastoma"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6674-1501","authenticated-orcid":false,"given":"Siddharth","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiswarya","family":"Nag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Lucke-Wold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,1]]},"reference":[{"issue":"1","key":"3849_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/medsci12010001","volume":"12","author":"S Shah","year":"2023","unstructured":"Shah S. Novel therapies in glioblastoma treatment: review of glioblastoma; current treatment options; and novel oncolytic viral therapies. Med Sci (Basel). 2023;12(1):1. https:\/\/doi.org\/10.3390\/medsci12010001.","journal-title":"Med Sci (Basel)"},{"issue":"4","key":"3849_CR2","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-12-3002","volume":"19","author":"H Ohgaki","year":"2013","unstructured":"Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013;19(4):764\u201372. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3002. (Epub 2012 Dec 3).","journal-title":"Clin Cancer Res"},{"issue":"10","key":"3849_CR3","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1001\/jamaoncol.2022.2844","volume":"8","author":"TR Berger","year":"2022","unstructured":"Berger TR, Wen PY, Lang-Orsini M, Chukwueke UN. World Health Organization 2021 classification of central nervous system tumors and implications for therapy for adult-type gliomas: a review. JAMA Oncol. 2022;8(10):1493\u2013501. https:\/\/doi.org\/10.1001\/jamaoncol.2022.2844.","journal-title":"JAMA Oncol"},{"issue":"32","key":"3849_CR4","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","volume":"31","author":"MR Gilbert","year":"2013","unstructured":"Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013;31(32):4085\u201391. https:\/\/doi.org\/10.1200\/JCO.2013.49.6968. (Epub 2013 Oct 7).","journal-title":"J Clin Oncol."},{"issue":"16","key":"3849_CR5","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.3390\/cancers16162892","volume":"16","author":"S Shah","year":"2024","unstructured":"Shah S, Lucke-Wold B. Image-guided mesenchymal stem cell sodium iodide symporter (NIS) radionuclide therapy for glioblastoma. Cancers (Basel). 2024;16(16):2892. https:\/\/doi.org\/10.3390\/cancers16162892.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"3849_CR6","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.7314\/apjcp.2014.15.6.2793","volume":"15","author":"AS Pashaki","year":"2014","unstructured":"Pashaki AS, Hamed EA, Mohamadian K, Abassi M, Safaei AM, Torkaman T. Efficacy of high dose radiotherapy in post-operative treatment of glioblastoma multiform\u2014a single institution report. Asian Pac J Cancer Prev. 2014;15(6):2793\u20136. https:\/\/doi.org\/10.7314\/apjcp.2014.15.6.2793.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"11","key":"3849_CR7","doi-asserted-by":"publisher","first-page":"5694","DOI":"10.3390\/ijms25115694","volume":"25","author":"S Shah","year":"2024","unstructured":"Shah S, Mansour HM, Aguilar TM, Lucke-Wold B. Advances in anti-cancer drug development: metformin as anti-angiogenic supplemental treatment for glioblastoma. Int J Mol Sci. 2024;25(11):5694. https:\/\/doi.org\/10.3390\/ijms25115694.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3849_CR8","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.3390\/ijms22041831","volume":"22","author":"M Tilak","year":"2021","unstructured":"Tilak M, Holborn J, New LA, Lalonde J, Jones N. Receptor tyrosine kinase signaling and targeting in glioblastoma multiforme. Int J Mol Sci. 2021;22(4):1831. https:\/\/doi.org\/10.3390\/ijms22041831.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"3849_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.603911","volume":"9","author":"B Huang","year":"2021","unstructured":"Huang B, Li X, Li Y, Zhang J, Zong Z, Zhang H. Current immunotherapies for glioblastoma multiforme. Front Immunol. 2021;9(11): 603911. https:\/\/doi.org\/10.3389\/fimmu.2020.603911.","journal-title":"Front Immunol"},{"issue":"1","key":"3849_CR10","doi-asserted-by":"publisher","DOI":"10.31031\/NACS.2024.08.000678","volume":"8","author":"S Shah","year":"2024","unstructured":"Shah S. Recent advances in the therapeutic approaches of glioblastoma multiforme. Nov Appro Can Study NACS. 2024;8(1): 000678. https:\/\/doi.org\/10.31031\/NACS.2024.08.000678.","journal-title":"Nov Appro Can Study NACS."},{"issue":"10","key":"3849_CR11","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.3390\/cancers14102412","volume":"14","author":"S Grochans","year":"2022","unstructured":"Grochans S, Cybulska AM, Simi\u0144ska D, Korbecki J, Kojder K, Chlubek D, et al. Epidemiology of glioblastoma multiforme\u2014literature review. Cancers (Basel). 2022;14(10):2412. https:\/\/doi.org\/10.3390\/cancers14102412.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"3849_CR12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.21037\/cco-23-82","volume":"12","author":"T Kutuk","year":"2023","unstructured":"Kutuk T, Atak E, La Rosa A, Kotecha R, Mehta MP, Chuong MD. Tumor treating fields: narrative review of a promising treatment modality for cancer. Chin Clin Oncol. 2023;12(6):64. https:\/\/doi.org\/10.21037\/cco-23-82. (Epub 2023 Nov 2).","journal-title":"Chin Clin Oncol."},{"issue":"20","key":"3849_CR13","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1158\/0008-5472.CAN-22-0887","volume":"82","author":"JC Moser","year":"2022","unstructured":"Moser JC, Salvador E, Deniz K, Swanson K, Tuszynski J, Carlson KW, et al. The mechanisms of action of tumor treating fields. Cancer Res. 2022;82(20):3650\u20138. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-0887.","journal-title":"Cancer Res"},{"issue":"4","key":"3849_CR14","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41416-020-01136-5","volume":"124","author":"O Rominiyi","year":"2021","unstructured":"Rominiyi O, Vanderlinden A, Clenton SJ, Bridgewater C, Al-Tamimi Y, Collis SJ. Tumour treating fields therapy for glioblastoma: current advances and future directions. Br J Cancer. 2021;124(4):697\u2013709. https:\/\/doi.org\/10.1038\/s41416-020-01136-5. (Epub 2020 Nov 4. Erratum in: Br J Cancer. 2021 Aug;125(4):623. 10.1038\/s41416-021-01451-5).","journal-title":"Br J Cancer"},{"issue":"10","key":"3849_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.arabjc.2021.103386","volume":"14","author":"E Mahgoub","year":"2021","unstructured":"Mahgoub E, Hussain A, Sharifi M, Falahati M, Marei HE, Hasan A. The therapeutic effects of tumor treating fields on cancer and noncancerous cells. Arab J Chem. 2021;14(10): 103386. https:\/\/doi.org\/10.1016\/j.arabjc.2021.103386.","journal-title":"Arab J Chem"},{"issue":"3","key":"3849_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.4103\/glioma.glioma_12_22","volume":"5","author":"Y Cao","year":"2022","unstructured":"Cao Y, Wu H, Tang B, Li M, Wan Y, Duan J, et al. Progress on TTFields combined with other therapies for glioblastoma treatment: a narrative review. Glioma. 2022;5(3):90\u20138. https:\/\/doi.org\/10.4103\/glioma.glioma_12_22.","journal-title":"Glioma"},{"issue":"7","key":"3849_CR17","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00262-020-02534-7","volume":"69","author":"T Voloshin","year":"2020","unstructured":"Voloshin T, Kaynan N, Davidi S, Porat Y, Shteingauz A, Schneiderman RS, et al. Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. Cancer Immunol Immunother. 2020;69(7):1191\u2013204. https:\/\/doi.org\/10.1007\/s00262-020-02534-7. (Epub 2020 Mar 6).","journal-title":"Cancer Immunol Immunother."},{"key":"3849_CR18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e14032","author":"AFG Ramirez","year":"2024","unstructured":"Ramirez AFG, Tang CC, Kong XT, Bota DA, Chang PD. Deep learning for 4D modeling of glioblastoma multiforme with tumor treating fields (TTFields) therapy. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.e14032.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3849_CR19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/19714009231207083","volume":"37","author":"M Iv","year":"2024","unstructured":"Iv M, Naya L, Sanan S, Van Buskirk SL, Nagpal S, Thomas RP, et al. Tumor treating fields increases blood-brain barrier permeability and relative cerebral blood volume in patients with glioblastoma. Neuroradiol J. 2024;37(1):107\u201318. https:\/\/doi.org\/10.1177\/19714009231207083. (Epub 2023 Nov 6).","journal-title":"Neuroradiol J."},{"issue":"10","key":"3849_CR20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3389\/fonc.2020.00411","volume":"21","author":"F Bokstein","year":"2020","unstructured":"Bokstein F, Blumenthal D, Limon D, Harosh CB, Ram Z, Grossman R. Concurrent tumor treating fields (TTFields) and radiation therapy for newly diagnosed glioblastoma: a prospective safety and feasibility study. Front Oncol. 2020;21(10):411. https:\/\/doi.org\/10.3389\/fonc.2020.00411.","journal-title":"Front Oncol"},{"issue":"1","key":"3849_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11060-023-04308-4","volume":"163","author":"H Fishman","year":"2023","unstructured":"Fishman H, Monin R, Dor-On E, Kinzel A, Haber A, et al. Tumor treating fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines. J Neurooncol. 2023;163(1):83\u201394. https:\/\/doi.org\/10.1007\/s11060-023-04308-4. (Epub 2023 May 2).","journal-title":"J Neurooncol."},{"issue":"5","key":"3849_CR22","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.ijrobp.2021.12.152","volume":"112","author":"M Glas","year":"2022","unstructured":"Glas M, Ballo MT, Bomzon Z, Urman N, Levi S, Lavy-Shahaf G, et al. The impact of tumor treating fields on glioblastoma progression patterns. Int J Radiat Oncol Biol Phys. 2022;112(5):1269\u201378. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.12.152. (Epub 2021 Dec 26).","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"23","key":"3849_CR23","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306\u201316. https:\/\/doi.org\/10.1001\/jama.2017.18718. (Erratum. In: JAMA. 2018 May1\u202f;319(17): 1824.doi:10.1001\/jama.2018.3431).","journal-title":"JAMA"},{"issue":"24","key":"3849_CR24","doi-asserted-by":"publisher","first-page":"10152","DOI":"10.1073\/pnas.0702916104","volume":"104","author":"ED Kirson","year":"2007","unstructured":"Kirson ED, Dbal\u00fd V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci USA. 2007;104(24):10152\u20137. https:\/\/doi.org\/10.1073\/pnas.0702916104. (Epub 2007 Jun 5).","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"3849_CR25","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1200\/JCO.22.00996","volume":"41","author":"MS Ahluwalia","year":"2023","unstructured":"Ahluwalia MS, Reardon DA, Abad AP, Curry WT, Wong ET, Figel SA, et al. Phase IIa study of SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma. J Clin Oncol. 2023;41(7):1453\u201365. https:\/\/doi.org\/10.1200\/JCO.22.00996. (Epub 2022 Dec 15).","journal-title":"J Clin Oncol."},{"issue":"10","key":"3849_CR26","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1093\/neuonc\/now038","volume":"18","author":"RI Jakacki","year":"2016","unstructured":"Jakacki RI, Cohen KJ, Buxton A, Krailo MD, Burger PC, Rosenblum MK, et al. Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children\u2019s Oncology Group ACNS0423 study. Neuro Oncol. 2016;18(10):1442\u201350. https:\/\/doi.org\/10.1093\/neuonc\/now038. (Epub 2016 Mar 22).","journal-title":"Neuro Oncol."},{"issue":"5","key":"3849_CR27","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.ijrobp.2019.04.008","volume":"104","author":"MT Ballo","year":"2019","unstructured":"Ballo MT, Urman N, Lavy-Shahaf G, Grewal J, Bomzon Z, Toms S. Correlation of tumor treating fields dosimetry to survival outcomes in newly diagnosed glioblastoma: a large-scale numerical simulation-based analysis of data from the phase 3 EF-14 randomized trial. Int J Radiat Oncol Biol Phys. 2019;104(5):1106\u201313. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.04.008. (Epub 2019 Apr 23).","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"3849_CR28","doi-asserted-by":"publisher","first-page":"CD013261","DOI":"10.1002\/14651858.CD013261.pub2","volume":"3","author":"C Hanna","year":"2020","unstructured":"Hanna C, Lawrie TA, Rogozi\u0144ska E, Kernohan A, Jefferies S, Bulbeck H, et al. Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis. Cochrane Database Syst Rev. 2020;3(3):CD013261. https:\/\/doi.org\/10.1002\/14651858.CD013261.pub2.","journal-title":"Cochrane Database Syst Rev."},{"issue":"45","key":"3849_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017759","volume":"98","author":"WL Wang","year":"2019","unstructured":"Wang WL, Aru N, Liu Z, Shen X, Ding YM, Wu SJ, et al. Prognosis of patients with newly diagnosed glioblastoma treated with molecularly targeted drugs combined with radiotherapy vs temozolomide monotherapy: a meta-analysis. Medicine (Baltimore). 2019;98(45): e17759. https:\/\/doi.org\/10.1097\/MD.0000000000017759.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"3849_CR30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamaoncol.2017.5082","volume":"4","author":"MJB Taphoorn","year":"2018","unstructured":"Taphoorn MJB, Dirven L, Kanner AA, Lavy-Shahaf G, Weinberg U, Taillibert S, et al. Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4(4):495\u2013504. https:\/\/doi.org\/10.1001\/jamaoncol.2017.5082.","journal-title":"JAMA Oncol"},{"issue":"10","key":"3849_CR31","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/1477-7819-10-220","volume":"24","author":"AM Rulseh","year":"2012","unstructured":"Rulseh AM, Keller J, Klener J, Sroubek J, Dbal\u00fd V, Syr\u016f\u010dek M, et al. Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields. World J Surg Oncol. 2012;24(10):220. https:\/\/doi.org\/10.1186\/1477-7819-10-220.","journal-title":"World J Surg Oncol"},{"issue":"13","key":"3849_CR32","doi-asserted-by":"publisher","first-page":"1042888","DOI":"10.3389\/fneur.2022.1042888","volume":"9","author":"L She","year":"2023","unstructured":"She L, Gong X, Su L, Liu C. Effectiveness and safety of tumor-treating fields therapy for glioblastoma: A single-center study in a Chinese cohort. Front Neurol. 2023;9(13):1042888. https:\/\/doi.org\/10.3389\/fneur.2022.1042888.","journal-title":"Front Neurol"},{"issue":"3","key":"3849_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2217\/cns-2018-0010","volume":"7","author":"GF Guzauskas","year":"2018","unstructured":"Guzauskas GF, Salzberg M, Wang BC. Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients. CNS Oncol. 2018;7(3):23. https:\/\/doi.org\/10.2217\/cns-2018-0010. (Epub 2018 Aug 20).","journal-title":"CNS Oncol"},{"key":"3849_CR34","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.critrevonc.2017.01.005","volume":"111","author":"M Mehta","year":"2017","unstructured":"Mehta M, Wen P, Nishikawa R, Reardon D, Peters K. Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. Crit Rev Oncol Hematol. 2017;111:60\u20135. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.01.005. (Epub 2017 Jan 22).","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"3849_CR35","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3390\/cancers11020174","volume":"11","author":"D Fabian","year":"2019","unstructured":"Fabian D, Guillermo Prieto Eibl MDP, Alnahhas I, Sebastian N, Giglio P, Puduvalli V, et al. Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF): a review. Cancers (Basel). 2019;11(2):174. https:\/\/doi.org\/10.3390\/cancers11020174.","journal-title":"Cancers (Basel)."},{"issue":"14","key":"3849_CR36","doi-asserted-by":"publisher","first-page":"1345190","DOI":"10.3389\/fonc.2024.1345190","volume":"20","author":"J Wang","year":"2024","unstructured":"Wang J, Du Q, Chen J, Liu J, Gu Z, Wang X, et al. Tumor treating fields in glioblastoma: long-term treatment and high compliance as favorable prognostic factors. Front Oncol. 2024;20(14):1345190. https:\/\/doi.org\/10.3389\/fonc.2024.1345190.","journal-title":"Front Oncol"},{"issue":"16_suppl","key":"3849_CR37","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1200\/JCO.2024.42.16_suppl.2036","volume":"42","author":"O B\u00e4hr","year":"2024","unstructured":"B\u00e4hr O, Tabatabai G, Fietkau R, Goldbrunner R, Glas M. Tumor treating fields (TTFields) therapy in patients with glioblastoma: long-term survival results from TTFields in Germany in routine clinical care (TIGER) study. J Clin Oncol. 2024;42(16_suppl):2036\u20132036. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.2036.","journal-title":"J Clin Oncol"},{"issue":"10","key":"3849_CR38","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.21873\/anticanres.14597","volume":"40","author":"Y Liu","year":"2020","unstructured":"Liu Y, Strawderman MS, Warren KT, Richardson M, Serventi JN, Mohile NA, et al. Clinical efficacy of tumor treating fields for newly diagnosed glioblastoma. Anticancer Res. 2020;40(10):5801\u20136. https:\/\/doi.org\/10.21873\/anticanres.14597.","journal-title":"Anticancer Res"},{"issue":"48","key":"3849_CR39","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000036421","volume":"102","author":"G Olatunji","year":"2023","unstructured":"Olatunji G, Aderinto N, Adefusi T, Kokori E, Akinmoju O, Yusuf I, et al. Efficacy of tumour-treating fields therapy in recurrent glioblastoma: a narrative review of current evidence. Medicine (Baltimore). 2023;102(48): e36421. https:\/\/doi.org\/10.1097\/MD.0000000000036421.","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"3849_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.671972","volume":"27","author":"Z Ram","year":"2021","unstructured":"Ram Z, Kim CY, Hottinger AF, Idbaih A, Nicholas G, Zhu JJ. Efficacy and safety of tumor treating fields (TTFields) in elderly patients with newly diagnosed glioblastoma: subgroup analysis of the phase 3 EF-14 clinical trial. Front Oncol. 2021;27(11): 671972. https:\/\/doi.org\/10.3389\/fonc.2021.671972. (Erratum. In: Front Oncol. 2022Apr12; 12: 902929. 10.3389\/fonc.2022.902929).","journal-title":"Front Oncol"},{"issue":"1","key":"3849_CR41","doi-asserted-by":"publisher","first-page":"vdaa069","DOI":"10.1093\/noajnl\/vdaa069","volume":"2","author":"AB Lassman","year":"2020","unstructured":"Lassman AB, Joanta-Gomez AE, Pan PC, Wick W. Current usage of tumor treating fields for glioblastoma. Neuro-oncol Adv. 2020;2(1):vdaa069. https:\/\/doi.org\/10.1093\/noajnl\/vdaa069.","journal-title":"Neuro-oncol Adv"},{"issue":"10","key":"3849_CR42","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1080\/13696998.2019.1614933","volume":"22","author":"GF Guzauskas","year":"2019","unstructured":"Guzauskas GF, Pollom EL, Stieber VW, Wang BCM, Garrison LP Jr. Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study. J Med Econ. 2019;22(10):1006\u201313. https:\/\/doi.org\/10.1080\/13696998.2019.1614933.","journal-title":"J Med Econ"},{"issue":"2","key":"3849_CR43","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3390\/neurolint13020015","volume":"13","author":"A Makimoto","year":"2021","unstructured":"Makimoto A, Nishikawa R, Terashima K, Kurihara J, Fujisaki H, Ihara S, et al. Tumor-treating fields therapy for pediatric brain tumors. Neurol Int. 2021;13(2):151\u201365. https:\/\/doi.org\/10.3390\/neurolint13020015.","journal-title":"Neurol Int"},{"issue":"4","key":"3849_CR44","first-page":"1069","volume":"11","author":"M Wang","year":"2021","unstructured":"Wang M, Zhang C, Wang X, Yu H, Zhang H, Xu J, et al. Tumor-treating fields (TTFields)-based cocktail therapy: a novel blueprint for glioblastoma treatment. Am J Cancer Res. 2021;11(4):1069\u201386.","journal-title":"Am J Cancer Res"},{"key":"3849_CR45","doi-asserted-by":"publisher","first-page":"679702","DOI":"10.3389\/fonc.2021.679702","volume":"11","author":"NTN Gatson","year":"2021","unstructured":"Gatson NTN, Barnholtz-Sloan J, Drappatz J, Henriksson R, Hottinger AF, Hinoul P, et al. Tumor treating fields for glioblastoma therapy during the COVID-19 pandemic. Front Oncol. 2021;11:679702. https:\/\/doi.org\/10.3389\/fonc.2021.679702. (Published 2021 May 7).","journal-title":"Front Oncol."},{"issue":"11","key":"3849_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.670809","volume":"24","author":"R Blatt","year":"2021","unstructured":"Blatt R, Davidi S, Munster M, Shteingauz A, Cahal S, Zeidan A, et al. In vivo safety of tumor treating fields (TTFields) applied to the torso. Front Oncol. 2021;24(11): 670809. https:\/\/doi.org\/10.3389\/fonc.2021.670809.","journal-title":"Front Oncol"},{"issue":"5_suppl","key":"3849_CR47","doi-asserted-by":"publisher","first-page":"v112","DOI":"10.1093\/annonc\/mdx366.009","volume":"28","author":"R Stupp","year":"2017","unstructured":"Stupp R, Taphoorn M, Dirven L, Taillibert S, Honnorat J, Chen T, et al. Tumor treating fields (TTFields)\u2014a novel cancer treatment modality: translating preclinical evidence and engineering into a survival benefit with delayed decline in quality of life. Ann Oncol. 2017;28(5_suppl):v112. https:\/\/doi.org\/10.1093\/annonc\/mdx366.009.","journal-title":"Ann Oncol"},{"issue":"2","key":"3849_CR48","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/COC.0000000000000395","volume":"41","author":"SH Burri","year":"2018","unstructured":"Burri SH, Gondi V, Brown PD, Mehta MP. The evolving role of tumor treating fields in managing glioblastoma: guide for oncologists. Am J Clin Oncol. 2018;41(2):191\u20136. https:\/\/doi.org\/10.1097\/COC.0000000000000395.","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"3849_CR49","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3390\/brainsci12040499","volume":"12","author":"R Kassubek","year":"2022","unstructured":"Kassubek R, Mathieu R. First report of tumor treating fields (TTFields) therapy for glioblastoma in comorbidity with multiple sclerosis. Brain Sci. 2022;12(4):499. https:\/\/doi.org\/10.3390\/brainsci12040499.","journal-title":"Brain Sci"},{"issue":"3","key":"3849_CR50","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s11060-022-04033-4","volume":"158","author":"NA Oberheim-Bush","year":"2022","unstructured":"Oberheim-Bush NA, Shi W, McDermott MW, Grote A, Stindl J, Lustgarten L. The safety profile of tumor treating fields (TTFields) therapy in glioblastoma patients with ventriculoperitoneal shunts. J Neurooncol. 2022;158(3):453\u201361. https:\/\/doi.org\/10.1007\/s11060-022-04033-4. (Epub 2022 May 31).","journal-title":"J Neurooncol."},{"issue":"3","key":"3849_CR51","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11060-020-03540-6","volume":"148","author":"W Shi","year":"2020","unstructured":"Shi W, Blumenthal DT, Oberheim Bush NA, Kebir S, Lukas RV, Muragaki Y, et al. Global post-marketing safety surveillance of tumor treating fields (TTFields) in patients with high-grade glioma in clinical practice. J Neurooncol. 2020;148(3):489\u2013500. https:\/\/doi.org\/10.1007\/s11060-020-03540-6.","journal-title":"J Neurooncol"},{"key":"3849_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.958637","volume":"12","author":"S Goldman","year":"2022","unstructured":"Goldman S, Margol A, Hwang EI, Tanaka K, Suchorska B, Crawford JR, et al. Safety of tumor treating fields (TTFields) therapy in pediatric patients with malignant brain tumors: Post-marketing surveillance data. Front Oncol. 2022;12: 958637. https:\/\/doi.org\/10.3389\/fonc.2022.958637.","journal-title":"Front Oncol"},{"key":"3849_CR53","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.3389\/fonc.2020.01045","volume":"10","author":"ME Lacouture","year":"2020","unstructured":"Lacouture ME, Anadkat MJ, Ballo MT, Iwamoto F, Jeyapalan SA, La Rocca RV, et al. Prevention and management of dermatologic adverse events associated with tumor treating fields in patients with glioblastoma. Front Oncol. 2020;10:1045. https:\/\/doi.org\/10.3389\/fonc.2020.01045.","journal-title":"Front Oncol"},{"issue":"20","key":"3849_CR54","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000033830","volume":"102","author":"C Yang","year":"2023","unstructured":"Yang C, Zhang Q, Ma C, Huang Y, Ding HX, Lu JW, et al. Characteristics and management of tumor treating fields-related dermatological complications in patients with glioblastoma. Medicine. 2023;102(20): e33830. https:\/\/doi.org\/10.1097\/MD.0000000000033830.","journal-title":"Medicine"},{"issue":"1","key":"3849_CR55","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s12672-022-00555-5","volume":"13","author":"JJ Zhu","year":"2022","unstructured":"Zhu JJ, Goldlust SA, Kleinberg LR, Honnorat J, Oberheim Bush NA, Ram Z. Tumor treating fields (TTFields) therapy vs physicians\u2019 choice standard-of-care treatment in patients with recurrent glioblastoma: a post-approval registry study (EF-19). Discov Oncol. 2022;13(1):105. https:\/\/doi.org\/10.1007\/s12672-022-00555-5.","journal-title":"Discov Oncol"},{"issue":"1","key":"3849_CR56","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1186\/s12885-024-12042-x","volume":"24","author":"P Kumthekar","year":"2024","unstructured":"Kumthekar P, Lyleroehr M, Lacson L, Lukas RV, Dixit K, Stupp R, et al. A qualitative evaluation of factors influencing tumor treating fields (TTFields) therapy decision making among brain tumor patients and physicians. BMC Cancer. 2024;24(1):527. https:\/\/doi.org\/10.1186\/s12885-024-12042-x.","journal-title":"BMC Cancer"},{"key":"3849_CR57","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3389\/fneur.2019.01026","volume":"10","author":"J Onken","year":"2019","unstructured":"Onken J, Goerling U, Heinrich M, Pleissner S, Krex D, Vajkoczy P, et al. Patient reported outcome (PRO) among high-grade glioma patients receiving TTFields treatment: a two center observational study. Front Neurol. 2019;10:1026. https:\/\/doi.org\/10.3389\/fneur.2019.01026.","journal-title":"Front Neurol"},{"issue":"12","key":"3849_CR58","doi-asserted-by":"publisher","first-page":"e1426","DOI":"10.1634\/theoncologist.2017-0603","volume":"24","author":"Y Wang","year":"2019","unstructured":"Wang Y, Pandey M, Ballo MT. Integration of tumor-treating fields into the multidisciplinary management of patients with solid malignancies. Oncologist. 2019;24(12):e1426\u201336. https:\/\/doi.org\/10.1634\/theoncologist.2017-0603.","journal-title":"Oncologist"},{"key":"3849_CR59","doi-asserted-by":"publisher","first-page":"394","DOI":"10.25259\/SNI_674_2023","volume":"14","author":"A Colamaria","year":"2023","unstructured":"Colamaria A, Leone A, Fochi NP, Di Napoli V, Giordano G, Landriscina M, et al. Tumor treating fields for the treatment of glioblastoma: Current understanding and future perspectives. Surg Neurol Int. 2023;14:394. https:\/\/doi.org\/10.25259\/SNI_674_2023.","journal-title":"Surg Neurol Int"},{"issue":"15","key":"3849_CR60","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.3390\/cancers14153669","volume":"14","author":"X Guo","year":"2022","unstructured":"Guo X, Yang X, Wu J, Yang H, Li Y, Li J, et al. Tumor-treating fields in glioblastomas: past, present, and future. Cancers. 2022;14(15):3669. https:\/\/doi.org\/10.3390\/cancers14153669.","journal-title":"Cancers"},{"issue":"1","key":"3849_CR61","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40644-019-0259-8","volume":"19","author":"VS Soni","year":"2019","unstructured":"Soni VS, Yanagihara TK. Tumor treating fields in the management of Glioblastoma: opportunities for advanced imaging. Cancer Imaging. 2019;19(1):76. https:\/\/doi.org\/10.1186\/s40644-019-0259-8.","journal-title":"Cancer Imaging"},{"issue":"5","key":"3849_CR62","doi-asserted-by":"publisher","first-page":"e1813","DOI":"10.1002\/cnr2.1813","volume":"6","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Xing X, Zhou J, Jiang H, Cen P, Jin C, et al. Therapeutic potential of tumor treating fields for malignant brain tumors. Cancer Rep (Hoboken, NJ). 2023;6(5):e1813. https:\/\/doi.org\/10.1002\/cnr2.1813.","journal-title":"Cancer Rep (Hoboken, N.J.)"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03849-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-03849-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03849-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T14:35:12Z","timestamp":1750343712000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-03849-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":62,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["3849"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-03849-6","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,1]]},"assertion":[{"value":"6 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval (Research involving human participants and\/or animals) and Informed consent."}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}